Feedback
Settings

Settings

Goto Application

32,519 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 3,252
1.20240248083SALIVA PAIRED IMAGING TEST APPARATUS AND METHOD
US - 25.07.2024
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
 Appl.No 18422976 Applicant Oral Genome Corp. Inventor Tina Saw

An apparatus and method for remote saliva testing in a variety of environments. The test involves the healthcare provider and the patient. Included is a non-invasive method of saliva collection and result detection which allows healthcare providers to send test kits to patient homes for remote testing, monitoring and care decisions. The apparatus includes a dental saliva imaging test card paired with a web application downloaded to a smartphone. The system may be used at home or in the dental office. The smartphone interface walks patients and providers through the test with tutorials to accurately capture testing results. The imaging test card includes a plurality of test strips onto which the patient places saliva. The test strips are sensitized to look for certain biomarkers, some of which detect periodontal disease and elevated caries risk. Results from the test strips are photographed and are then uploaded to the application for analysis.

2.WO/2024/152113ANTIBODIES AND ANTIGEN BINDING FRAGMENTS COUPLED TO HOMOLOGOUS DIMERIZATION (HD) PEPTIDES FOR THE PREVENTION AND TREATMENT OF INFECTIOUS DISEASE
WO - 25.07.2024
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CA2024/050047 Applicant MORGAN, Alton C. Inventor MORGAN, Alton C.
Antibodies or antigen binding fragments against infectious diseases having a homologous dimerization (HD) peptide coupled thereto are disclosed, as well as methods of manufacture and uses thereof. The HD peptides may comprise (i) an amino acid sequence of a naturally occurring HD peptide, or a conservative variant thereof, (ii) an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide, or a conservative variant thereof, (iii) an amino acid sequence of a naturally occurring HD peptide with one or more hydrophilic substitutions, or (iv) an HD peptide dimer.
3.20240247033SARS-COV-2 RBD CONSTRUCTS
US - 25.07.2024
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 18002611 Applicant The Scripps Research Institute Inventor William SCHIEF

The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.

4.WO/2024/155814METHOD OF DETECTING DISEASE-ASSOCIATED MARKERS IN A LIQUID BIOPSY SAMPLE USING EXTRACELLULAR VESICLES
WO - 25.07.2024
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2024/012015 Applicant THE GENERAL HOSPITAL CORPORATION Inventor IM, Hyungsoon
The present disclosure relates to devices (e.g., nano-plasmonic chips having arrays of nanowells) and methods for the detection of cancer (e.g., CCA).
5.WO/2024/154784METHOD AND KIT FOR PREDICTING EFFICACY OF TREATMENT WITH IMMUNOTHERAPEUTIC AGENT ON PATIENT WITH MUCOSAL LESION
WO - 25.07.2024
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/JP2024/001302 Applicant NIHON UNIVERSITY Inventor KAWANA Kei
The present invention provides a novel method and kit for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion. The present invention is a method for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion, the method comprising a step for measuring the expression level of CD86 in a biological sample derived from a patient with a mucosal lesion. The present invention is a kit for use in the above method, the kit comprising a substance that binds specifically to CD86, or forward and reverse primers for amplifying nucleic acids encoding CD86.
6.WO/2024/154155COMPOSITION, SYSTEM AND METHOD FOR DNA AMPLIFICATION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX
WO - 25.07.2024
Int.Class C12Q 1/689
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6888for detection or identification of organisms
689for bacteria
 Appl.No PCT/IN2024/050054 Applicant ACRANNOLIFE GENOMICS PVT. LTD. Inventor RAMANI, Avinash
The present invention discloses a composition for amplification of specific DNA sequences of Mycobacterium tuberculosis complex from different biological samples. The present invention also discloses a system for rapid and accurate detection of Mycobacterium tuberculosis complex from different biological samples using naked eye, comprising means for DNA extraction, DNA amplification, DNA visualization. The present invention also discloses a method for rapid and accurate detection of Mycobacterium tuberculosis complex from different biological samples using naked eye, comprising DNA extraction, DNA amplification and DNA visualization.
7.WO/2024/155569ASSAYS FOR DETERMINING MILK ALLERGIES
WO - 25.07.2024
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No PCT/US2024/011582 Applicant ALLERGENIS, INC. Inventor KEARNEY, Paul
Methods of determining the milk phenotype of a subject, methods of determining prior to initiating oral immunotherapy (OIT) in a subject whether the subject will experience sustained unresponsiveness (SU) after completion of the OIT, and methods of determining a milk allergy threshold amount for a subject are presented herein.
8.WO/2024/152450MICROFLUIDIC MULTI-TARGET DETECTION SYSTEM BASED ON FLUIDIZED-BED MAGNETIC ENRICHMENT AND CDS/QDS@ZIF-8 PHYSICAL AMPLIFICATION
WO - 25.07.2024
Int.Class G01N 33/553
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
551the carrier being inorganic
553Metal or metal coated
 Appl.No PCT/CN2023/084156 Applicant INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES Inventor ZHOU, Lei
Disclosed in the present application is a microfluidic multi-target detection system based on fluidized-bed magnetic enrichment and CDs/QDs@ZIF-8 physical amplification. The system comprises capture magnetic particles, a fluidized-bed magnetic enrichment micro-fluidic chip, a CDs/QDs@ZIF-8 biological tracer and a dissolution release agent, wherein the capture magnetic particles can synchronously separate and enrich multiple targets among a large-volume sample under test in the fluidized-bed magnetic enrichment micro-fluidic chip; the CDs/QDs@ZIF-8 biological tracer can respectively identify multiple enriched targets by loading different carbon dot or quantum dot fluorescence signals; and each identification signal is enhanced by using the dissolution release agent, such that the multiple targets in said sample can be detected with high sensitivity; in addition, the system also has the characteristics of high integration and a high degree of automation.
9.20240241123SYSTEMS AND METHODS FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES
US - 18.07.2024
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
 Appl.No 18618944 Applicant Analiza, Inc. Inventor Arnon Chait

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, the virus may partition into one or more phases. In some cases, a virus-binding moiety facilitates partitioning of the virus. The phases may be assayed to determine the virus based on, e.g., quantitative or qualitative assessments of the distribution of virus-binding and/or signaling moieties. The virus-binding moiety may be attached to particles that may form a complex around a virus. The complex may be detectable without a signaling moiety (e.g., as a color change) in some embodiments. In some cases, more than one virus may be determined. For example, a virus-binding moiety may substantially alter the partitioning behavior of one virus or complex, relative to another, by being selective for the first virus.

10.20240239872COMBINATION OF PVY MONOCLONAL ANTIBODIES CAPABLE OF RECOGNIZING DIFFERENT ANTIGENIC DETERMINANTS, AND USE THEREOF
US - 18.07.2024
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 18384035 Applicant Shandong Agricultural University Inventor Xiangdong LI

The invention discloses a combination of PVY monoclonal antibodies capable of recognizing different antigenic determinants, and a use thereof, and belongs to the biotechnological field. Monoclonal antibodies N1, M1, M2, M3 and C1 obtained in the invention have specific CDRs, and are significantly different from existing reported monoclonal antibodies. The five monoclonal antibodies and a combination thereof can recognize all or most PVY isolates which have been reported, thus reducing the possibility of detection omissions; and the five monoclonal antibodies do not react with other congeneric viruses and non-congeneric viruses, thus reducing the possibility of detection errors. Therefore, the monoclonal antibodies and the combination thereof can realize accurate PVY detection.

# -